
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions Inc has exhibited significant revenue growth, with Cell Processing revenue increasing to $23.0 million, representing a 28% year-over-year growth, while evo and Thaw revenue reached $2.5 million, marking a 44% increase year-over-year. Additionally, management has enhanced its 2025 revenue guidance to a range of $100-103 million, indicative of expected ongoing growth with Cell Processing projected at $91.0-93.0 million and evo and Thaw at $9.0-10.0 million. Furthermore, the company anticipates a reduction in net loss and continued expansion of adjusted EBITDA margins, highlighting a strong growth trajectory and financial improvement.
Bears say
BioLife Solutions Inc's outlook is negatively affected by several fundamental risks, particularly the potential for lower-than-projected growth in products and services, which could hinder revenue generation. The company's net loss for the period was significantly greater than forecasts, totaling $15.8 million, attributed largely to substantial R&D expenses linked to the PanTHERA transaction. Furthermore, the revised revenue guidance for FY2025 reflects a decrease of approximately $8 million in expected revenue, indicating a challenging growth trajectory, particularly for its primary revenue driver, the Cell Processing platform.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares